Back to the future: Revisiting parathyroid hormone and calcitonin control of bone remodeling

Hormone and Metabolic Research

Volumn 42, Issue 5, 2010, Pages 299-306

  Paula, F J A D ^a   Rosen, C J ^a  

^a Maine Medical Center Research Institute   (United States)

Author keywords

Bone mineral density; Calcitonin; Osteoblast; Osteoporosis; Parathyroid hormone

Indexed keywords

ALPHA CALCITONIN GENE RELATED PEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; SALCATONIN;

ANALGESIC ACTIVITY; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE PAIN; BONE REMODELING; BONE TURNOVER; CALCIUM METABOLISM; CIRCADIAN RHYTHM; CLINICAL TRIAL; DRUG ACTIVITY; DRUG APPROVAL; DRUG INHIBITION; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; FRACTURE; FRAGILITY FRACTURE; HUMAN; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PARATHYROID FUNCTION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; VERTEBRA FRACTURE;

ANIMALS; BONE AND BONES; BONE DEVELOPMENT; BONE REMODELING; CALCITONIN; HUMANS; OSTEOBLASTS; OSTEOCYTES; PARATHYROID HORMONE;

EID: 77952003910     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0030-1248255     Document Type: Review

References (72)

1. Torres PU. The need for reliable serum parathyroid hormone measurements. Kidney Int 2006 70 240-243 (Pubitemid 44086572)
2. Lanske B, Razzaque MS. Vitamin D and aging: old concepts and new insights. J Nutr Biochem 2007 18 771-777 (Pubitemid 350138431)
3. Copp DH, Cameron EC. Demonstration of a hypocalcemic factor (calcitonin) in commercial parathyroid extract. Science 1961 134 2038
4. Neher R, Riniker B, Maier R, Byfield PG, Gudmundsson TV, MacIntyre I. Human calcitonin. Nature 1968 220 984-986
5. Lerner UH. Deletions of genes encondig calcitonin/-CGRP, amylin and calcitonin receptor have given new and unexpected insights into the function of calcitonin receptors and calcitonin receptor-like receptor in bone. J Musculoskelet Neuronal Interact 2006 6 87-95
6. Shinki T, Ueno Y, DeLuca HF, Suda T. Calcitonin is a major regulator for the expression of renal 25-hydroxyvitamin D3-1alpha-hydroxylase gene in normocalcemic rats. Proc Natl Acad Sci USA 1999 96 8253-8258 (Pubitemid 29328441)
7. Chambers TJ, Chambers JC, Symonds J, Darby JA. The effect of human calcitonin on the cytoplasmic spreading of rat osteoclasts. J Clin Endocrinol Metab 1986 63 1080-1085 (Pubitemid 17173041)
8. Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endoc Rev 1996 17 533-585
9. Woodrow JP, Sharpe CJ, Fudge NJ, Hoff AO, Gagel RF, Kovacs CS. Calcitonin plays a critical role in regulating skeletal mineral metabolism during lactation. Endocrinology 2006 147 4010-4021
10. Davey RA, Turner AG, McManus JF, Maria-Chiu WS, Tjahyono F, Moore AJ, Atkins GJ, Anderson PH, Ma C, Glatt V, MacLean HE, Vincent C, Bouxsein M, Morris HA, Findlay DM, Zajac JD. Calcitonin receptor plays a physiological role to protect against hypercalcemia in mice. J Bone Miner Res 2008 23 1182-1193 (Pubitemid 352040174)
11. Daripa M, Paula FJ, Rufino AC, Foss MC. Impact of congenital calcitonin deficiency due to dysgenetic hypothyroidism on bone mineral density. Braz J Med Biol Res 2004 37 61-68 (Pubitemid 38240145)
12. Hurley DL, Tiegs RD, Wahner HW, Heath III H. Axial and appendicular bone mineral density in patients with long-term deficiency or excess of calcitonin. N Engl J Med 1987 317 537-541
13. Hoff AO, Catala-Lehnen P, Thomas PM, Priemel M, Rueger JM, Nasonkin I, Bradley A, Hughes MR, Ordonez N, Cote GJ, Amling M, Gagel RF. Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest 2002 110 1849-1857 (Pubitemid 36076492)
14. Dacquin R, Davey RA, Laplace C, Levasseur R, Morris HA, Goldring SR, Gebre-Medhim S, Galson DL, Zajac JD, Karsenty G. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol 2004 164 509-514 (Pubitemid 38233312)
15. Owan I, Ibaraki K. The role of calcitonin gene-related peptide (CGRP) in macrophages: the presence of functional receptors and effects on proliferation and differentiation into osteoclast-like cells. Bone Miner 1994 24 151-164 (Pubitemid 2049849)
16. Cornish J, Callon KE, Lin CQ, Xiao CL, Gamble GD, Cooper GJ, Reid IR. Comparision of the effects of calcitonin gene-related peptide to osteoblasts increases bone density in mice. J bone Miner Res 1999 14 1302-1309
17. Gagel RF, Hoff AO, Huang SE, Cote GJ. Deletion of calcitonin/CGRP gene causes a profound cortical resorption phenotype in mice. J Bone Miner Res 2007 22 S1-S35
18. Huebner AK, Schinke T, Matthias P, Schilling S, Schilling AF, Emeson RB, Rueger JM, Amling M. Calcitonin deficiency in mice progressively results in high bone turnover. J Bone Miner Res 2006 21 1924-1934 (Pubitemid 44851569)
19. PROOF Study Group. Chesnut III CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the PROOF study. Am J Med 2000 109 267-276
20. Karsdal MA, Henriksen K, Arnold M, Christiansen C. Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs 2008 22 137-144 (Pubitemid 351692844)
21. Mehta NM, Malootian A, Gilligan JP. Calcitonin for osteoporosis and bone pain. Curr Pharm Des 2003 9 2659-2676
22. Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon Calcitonin. BMC Clin Pharmacol 2008 8 5
23. Mustata G, Dihn SM. Approach to oral drug delivery for challenging molecules. Crit Rev Ther Drug Carrier Syst 2006 23 111-135 (Pubitemid 44403815)
24. Wu SJ, Robinson JR. Transcellular and lipophilic complex-enhanced intestinal absorption of human growth hormone. Pharm Res 1999 16 1266-1272 (Pubitemid 29393617)
25. Tank LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 2004 19 1531-1538 (Pubitemid 41094356)
26. Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C. Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitonin. BMC Clin Pharmacol 2008 8 12
27. Brown EM. The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. Subcell Biochem 2007 45 139-167
28. Lanna CM, Paula FJ, Montenegro RM Jr, Moreira AC, Foss MC. Parathyroid hormone secretion in chronic human endogenous hypercortisolism. Braz J Med Biol Res 2002 35 229-236
29. Paula FJ, Lanna CM, Shuhama T, Foss MC. Effect of metabolic control on parathyroid hormone secretion in diabetic patients. Braz J Med Biol Res 2001 34 1139-1145 (Pubitemid 33632097)
30. Jppner H, Abou-Samra AB, Freeman M, Kong XF, Schipani E, Richards J, Kolakowski LF Jr, Hock J, Potts JT Jr, Kronenberg HM. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991 254 1024-1026 (Pubitemid 21917436)
31. Anastasilakis AD, Efstathiadou Z, Plevraki E, Koukoulis GN, Slavakis A, Kita M, Avramidis A. Effect of exogenous intermittent recombinant human PTH 134 administration and chronic endogenous parathyroid hormone excess on glucose homeostasis and insulin sensitivity. Horm Metab Res 2008 40 702-707
32. Cha H, Jeong HJ, Jang SP, Kim JY, Yang DK, Oh JG, Park WJ. PTH accelerates decompensation following left ventricular hypertrophy. Exp Mol Med 2010 42 61-68
33. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J, Silverberg SJ. The Natural History of Primary Hyperparathyroidism with or without Parathyroid Surgery after 15 Years. J Clin Endocrinol Metab 2008 93 3462-3470
34. de Albuquerque Taveira AT, Fernandes MI, Galvo LC, Sawamura R, de Mello Vieira E, de Paula FJ. Impairment of bone mass development in children with chronic cholestatic liver disease. Clin Endocrinol 2007 66 518-523 (Pubitemid 46434932)
35. Doga M, Mazziotti G, Bonadonna S, Patelli I, Bilezikian JP, Canalis E, Giustina A. Prevention and treatment of glucocorticoid-induced osteoporosis. J Endocrinol Invest 2008 31 535-538
36. Haagensen AL, Feldman HA, Ringelheim J, Gordon CM. Low prevalence of vitamin D deficiency among adolescents with anorexia nervosa. Osteoporos Int 2008 19 289-294 (Pubitemid 351199188)
37. Oelzner P, Lehmann G, Eidner T, Franke S, Mller A, Wolf G, Hein G. Hypercalcemia in rheumatoid arthritis: relationship with disease activity and bone metabolism. Rheumatol Int 2006 26 908-915 (Pubitemid 43962121)
38. Kajil H, Yamauchi M, Chihara K, Sugimoto T. Relationship between endogenous parathyroid hormone and bone metabolism/geometry in female patients treated with glucocorticoid. Horm Metab Res 2008 40 60-65 (Pubitemid 351204827)
39. Reusch J, Ackermann H, Badenhoop K. Cyclic changes of vitamin D and PTH are primarily regulated by solar radiation: 5-Year analysis of a German (50 N) population. Horm Metab Res 2009 41 402-407
40. Tam CS, Heersche JN, Murray TM, Parsons JA. Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology 1982 110 506-512
41. Anastasilakis AD, Polyzos SA, Avramidis A, Papatheodorou A, Terpos E. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide. Horm Metab Res 2009 41 559-562
42. Kulkarni NH, Wei T, Kumar A, Dow ER, Stewart TR, Shou J, NCho M, Sterchi DL, Gitter BD, Higgs RE, Halladay DL, Engler TA, Martin TJ, Bryant HU, Ma YL, Onyia JE. Changes in osteoblast, chondrocyte, and adipocyte lineages mediate the bone anabolic actions of PTH and small molecule GSK-3 inhibitor. J Cell Biochem 2007 102 1504-1518 (Pubitemid 350223952)
43. Rickard DJ, Wang FL, Rodriguez-Rojas AM, Wu Z, Trice WJ, Hoffman SJ, Votta B, Stroup GB, Kumar S, Nuttall ME. Intermittent treatment with parathyroid hormone (PTH) as well as a non-peptide small molecule agonist of the PTH1 receptor inhibits adipocyte differentiation in human bone marrowstromal cells. Bone 2006 39 1361-1372 (Pubitemid 44827918)
44. Allan EH, Husler KD, Wei T, Gooi JH, Quinn JM, Crimeen-Irwin B, Pompolo S, Sims NA, Gillespie MT, Onyia JE, Martin TJ. EphrinB2 regulation by PTH and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res 2008 23 1170-1181 (Pubitemid 352040173)
45. Logue FC, Fraser WD, OReilly DS, Cameron DA, Kelly AJ, Beastall GH. The circadian rhythm of intact parathyroid hormone-(184): temporal correlation with prolactin secretion in normal men. J Clin Endocrinol Metab 1990 71 1556-1560
46. Fraser WD, Logue FC, Christie JP, Gallacher SJ, Cameron D, OReilly DS, Beastall GH, Boyle IT. Alteration of the circadian rhythm of intact parathyroid hormone and serum phosphate in women with established postmenopausal osteoporosis. Osteoporos Int 1998 8 121-126 (Pubitemid 28230433)
47. Lobaugh B, Neelon FA, Oyama H, Buckley N, Smith S, Christy M, Leight GS Jr. Circadian rhythms for calcium, inorganic phosphorus, and parathyroid hormone in primary hyperparathyroidism: functional and practical considerations. Surgery 1989 106 1009-1016 (Pubitemid 20012375)
48. Prank K, Nowlan SJ, Harms HM, Kloppstech M, Brabant G, Hesch RD, Sejnowski TJ. Time series prediction of plasma hormone concentration. Evidence for differences in predictability of parathyroid hormone secretion between osteoporotic patients and normal controls. J Clin Invest 1995 95 2910-2919
49. Silverberg SJ, Shane E, de la Cruz L, Segre GV, Clemens TL, Bilezikian JP. Abnormalities in parathyroid hormone secretion and 1,25-diydroxyvitamin D3 formation in women with osteoporosis. N Engl J Med 1989 320 277-281 (Pubitemid 19045551)
50. Pereira LC, Pereira FA, S MF, Foss MC, dePaula FJ. Parathyroid hormone secretion in women in late menopause submitted to EDTA-induced hypocalcemia. Maturitas 2008 59 91-94
51. Hamilton JW, Jilka RL, MacGregor RR. Cleavage of parathyroid hormone to the 134 and 3584 fragments by cathepsin D-like activityin bovine parathyroid gland extracts. Endocrinology 1983 113 285-292
52. Friedman PA, Goodman WG. PTH (184)/PTH (784): A balance of power. Am J Physiol Renal Physiol 2006 290 F975-F984
53. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007 40 1434-1446
54. Hock JM, Onyia JE, Miller B, Hulman J, Herring J, Chandrasekhar S, Harvey AK, Gunness M. Anabolic PTH targets proliferating cells of the primary spongiosa in young rats, and increases the number differentiating into osteoblasts. J Bone Miner Res 1994 9 S412
55. Schmidt IU, Dobnig H, Turner RT. Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. Endocrinology 1995 136 5127-5133
56. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Robertson PK, Weistein RS, OBrien CA, Manolagas SC, Jilka RL. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts: a putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003 278 50259-50272 (Pubitemid 37548867)
57. Krishnan V, Moore TL, Ma YL, Helvering LM, Frolik CA, Valasek KM, Ducy P, Geiser AG. Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signaling. Mol Endocrinol 2003 17 423-435 (Pubitemid 36315636)
58. Rosen CJ. Insulin-like growth factor I and bone mineral density: Experience from animal models and human observational studies. Best Pract Res Clin Endocrinol Metab 2004 18 423-435
59. Wang Y, Nishida S, Boudignon BM, Burghardt A, Elalieh HZ, Hamilton MM, Majundar S, Halloran BP, Clemens TL, Bikle DD. IGF-I receptor is required for the anabolic actions of parathyroid Hormoneon Bone. J Bone Miner Res 2007 22 1329-1337 (Pubitemid 351339678)
60. Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 2001 142 4349-4356 (Pubitemid 32907063)
61. Yakar S, Brouxsein ML, Canalis E, Sun H, Glatt V, Gundberg C, Cohen P, Hwanq D, Boisclair Y, Leroith D, Rosen CJ. The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol 2006 189 289-299 (Pubitemid 43757787)
62. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999 20 345-357 (Pubitemid 30649812)
63. Rodan GA, Martin TJ. Role of osteoblasts in hormonal control of bone resorption a hypothesis [letter]. Calcif Tissue Int 1982 34 311
64. Rubin J, Ackert-Bicknell CL, Zhu L, Fan X, Murphy TC, Nanes MS, Marcus R, Holloway L, Beamer WG, Rosen CJ. IGF-I regulates osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand in vitro and OPG in vivo. J Clin Endocrinol Metab 2002 87 4273-4279
65. Li X, Liu H, Qin L, Tamasi J, Bergenstock M, Shapses S, Feyen JHM, Notterman DA, Partridge NC. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J Biol Chem 2007 282 33086-33097 (Pubitemid 350159330)
66. Li X, Qin L, Bergenstock M, Bevelock LM, Novack DV, Partridge NC. Parathyroid Hormone Stimulates Osteoblastic Expression of MCP-1 to Recruit and Increase the Fusion of Pre/Osteoclasts. J Biol Chem 2007 282 33098-33106 (Pubitemid 350159306)
67. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ, PaTH Study Investigators. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003 349 1207-1215 (Pubitemid 37152030)
68. Winkler DG, Sutherland Mk, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003 22 6267-6276 (Pubitemid 37522584)
69. Kerachian MA, Sguin C, Harvey EJ. Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol 2009 114 121-128
70. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, OBrien CA, Manolagas SC, Jilka RL. Chronic elevation of parathyroid hormone in mice reduces expression of scherostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005 146 4577-4583 (Pubitemid 41446595)
71. Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone 2005 37 148-158 (Pubitemid 40962421)
72. OBrien CA, Plotkin LI, Galli C, Goelner JJ, Gortazar AR, Allen MR, Robling A, Brouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 2008 3 e2942